Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy in patients with resectable liver metastases from colorectal cancer

  • Published:
Current Colorectal Cancer Reports

Abstract

New chemotherapy drugs and, more recently, targeted therapies have significantly improved the outcome of patients with resected stage III colon cancer (adjuvant chemotherapy) and patients with unresectable metastases (palliative therapy). These advances raise several questions about the place of chemotherapy after and before surgery in patients with resectable liver metastases. To date, only a combined intra-arterial plus systemic fluoropyrimidine-based chemotherapy regimen has clearly demonstrated a relapse-free survival benefit. Yet, this approach is restricted to specialized centers, mainly because of technical difficulties and locoregional toxicities. The role of systemic use of oxaliplatin- and irinotecan-based regimens is currently under investigation. Planned trials will assess the role of anti-angiogenic and anti-epidermal growth factor receptor agents. We review the main trials performed in patients with resectable metastases, and discuss their potent impact on clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.

    Article  PubMed  Google Scholar 

  2. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759–766.

    Article  PubMed  Google Scholar 

  3. Ackerman NB: The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974, 75:589–596.

    PubMed  CAS  Google Scholar 

  4. Miyanari N, Mori T, Takahashi K, Yasuno M: Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 2002, 45:1503–1509.

    Article  PubMed  Google Scholar 

  5. O’Connell MJ, Nagorney DM, Bernath AM, et al.: Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998, 16:2528–2533.

    PubMed  CAS  Google Scholar 

  6. Van Riel JM, van Groeningen CJ, Albers SH, et al.: Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. Ann Oncol 2000, 11:1563–1570.

    Article  PubMed  Google Scholar 

  7. Leonard GD, Brenner B, Kemeny NE: Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005, 23:2038–2048.

    Article  PubMed  CAS  Google Scholar 

  8. Link KH, Pillasch J, Formentini A, et al.: Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 1999, 25:381–388.

    Article  PubMed  CAS  Google Scholar 

  9. Meric F, Patt YZ, Curley SA, et al.: Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000, 7:490–495.

    Article  PubMed  CAS  Google Scholar 

  10. Elias D, de Baere T, Sideris L, Ducreux M: Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surg Clin North Am 2004, 84:607–625.

    Article  PubMed  Google Scholar 

  11. Moosman N, Kern W, Waggershauser T, et al.: Hepatic infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final results of a phase I/II study [abstract]. Proc ASCO 2005, 23:2326.

    Google Scholar 

  12. Nonami T, Takeuchi Y, Yasui M, et al.: Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma. Semin Oncol 1997, 24(2 suppl 6):S6–130-S6-134.

    PubMed  CAS  Google Scholar 

  13. Ambiru S, Miyazaki M, Ito H, et al.: Adjuvant regional chemotherapy after hepatic resection for colorectal metastases. Br J Surg 1999, 86:1025–1031.

    Article  PubMed  CAS  Google Scholar 

  14. Heslin MJ, Medina-Franco H, Parker M, et al.: Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. Arch Surg 2001, 136:318–323.

    Article  PubMed  CAS  Google Scholar 

  15. Kokudo N, Seki M, Ohta H, et al.: Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases. Ann Surg Oncol 1998, 5:706–712.

    Article  PubMed  CAS  Google Scholar 

  16. Curley SA, Roh MS, Chase JL, Hohn DC: Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am J Surg 1993, 166:743–746.

    Article  PubMed  CAS  Google Scholar 

  17. Gambiez L, Denimal F, Karoui M, et al.: Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients. Chirurgie 1999, 124:640–648.

    Article  PubMed  CAS  Google Scholar 

  18. Tono T, Kanoh T, Ohnishi T, et al.: Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy. J Surg Oncol 2004, 88:248–255.

    Article  PubMed  Google Scholar 

  19. Tono T, Hasuike Y, Ohzato H, et al.: Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer 2000, 88:1549–1556.

    Article  PubMed  CAS  Google Scholar 

  20. Kemeny N, Conti JA, Sigurdson E, et al.: A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer 1993, 71:1964–1971.

    Article  PubMed  CAS  Google Scholar 

  21. Scaife CL, Curley SA, Izzo F, et al.: Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 2003, 10:348–354.

    Article  PubMed  Google Scholar 

  22. Rougier P, Laplanche A, Huguier M, et al.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10:1112–1118.

    PubMed  CAS  Google Scholar 

  23. Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J: Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999, 384:243–249.

    Article  PubMed  CAS  Google Scholar 

  24. Lorenz M, Muller HH, Schramm H, et al.: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998, 228:756–762.

    Article  PubMed  CAS  Google Scholar 

  25. Kusunoki M, Yanagi H, Noda M, et al.: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 2000, 89:1228–1235.

    Article  PubMed  CAS  Google Scholar 

  26. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039–2048.

    Article  PubMed  CAS  Google Scholar 

  27. Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 2005, 352:734–735. Updated results of the study reported in 1999 (Kemeny et al. [26]). Main demonstration of the usefulness of chemotherapy after resection of liver metastases, but technical limits of intra-arterial chemotherapy.

    Article  PubMed  CAS  Google Scholar 

  28. Kemeny MM, Adak S, Gray B, et al.: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 2002, 20:1499–1505. Further evidence for the role of complementary chemotherapy, despite a high number of ineligible patients and accrual difficulties.

    Article  PubMed  Google Scholar 

  29. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309–318.

    Article  PubMed  CAS  Google Scholar 

  30. Kemeny NE, Jarnagin W, Gonen M, et al.: Phase I trial of hepatic arterial infusion with floxuridine and dexamethazone in combination with systemic oxaliplatin, fluorouracil plus leucovorin after resection of hepatic metastases from colorectal cancer. Proc ASCO 2005, 23:3579.

    Google Scholar 

  31. Martin RC, Edwards MJ, McMasters KM: Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver. Am J Surg 2004, 188:714–721.

    Article  PubMed  Google Scholar 

  32. Portier G, Rougier P, Milan C, et al.: Adjuvant systemic chemotherapy using 5-fluorouracil and folinic acid after resection of liver metastases from colorectal cancer origin [abstract]. Proc ASCO 2002, 20:528.

    Google Scholar 

  33. Langer B, Bleiberg H, Labianca R, et al.: Fluorouracil plus Lleucovorin versus observation after potentially curative resection of liver or lung metastases from colorectal cancer [abstract]. Proc ASCO 2002, 20:592.

    Google Scholar 

  34. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905–914.

    Article  PubMed  CAS  Google Scholar 

  35. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  36. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.

    PubMed  Google Scholar 

  37. Adam R, Avisar E, Ariche A, et al.: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8:347–353.

    Article  PubMed  CAS  Google Scholar 

  38. Giacchetti S, Itzhaki M, Gruia G, et al.: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999, 10:663–669.

    Article  PubMed  CAS  Google Scholar 

  39. Wein A, Riedel C, Bruckl W, et al.: Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003, 64:131–138.

    Article  PubMed  CAS  Google Scholar 

  40. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343–2351.

    Article  PubMed  CAS  Google Scholar 

  41. Wolmark N, Wieand S, Kuebler JP, et al.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07 [abstract]. Proc ASCO 2005, 23:3500.

    Google Scholar 

  42. Van Cutsem E, Labianca R, Hossfeld D, et al.: Randomized phase III trial comparing infused irinotecan/5-fluorouracil/ folinic acid versus 5-fluorouracil/folinic acid in stage III colon cancer [abstract]. Proc ASCO 2005, 23:8.

    Google Scholar 

  43. Ychou M, Raoul J, Douillard JY, et al.: A phase III randomized trial of LV5FU2 + CPT-11 vs LV5FU2 alone in adjuvant high risk colon cancer [abstract]. Proc ASCO 2005, 23:3502.

    Google Scholar 

  44. Bolton JS, Fuhrman GM: Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000, 231:743–751.

    Article  PubMed  CAS  Google Scholar 

  45. Taïeb J, Artru P, Paye F, et al.: Intensive chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005, 23:502–509. Phase II trial assessing the new regimens (6 FOLFOX followed by 6 FOLFIRI) in patients with resectable metastases. Promising schedule currently assessed in a phase III trial.

    Article  PubMed  CAS  Google Scholar 

  46. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  47. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group. Proc ASCO 2005, 23:2.

    Google Scholar 

  48. Chen HX, Mooney M, Boron M, et al.: Bevacizumab plus 5-FU/ leucovorin for advanced colorectal cancer that progressed after standard chemotherapies [abstract]. Proc ASCO 2004, 22:3515.

    Google Scholar 

  49. Takeda A, Stoeltzing O, Ahmad SA, et al.: Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 2002, 9:610–616.

    Article  PubMed  Google Scholar 

  50. Hecht JR, Trarbach T, Jaeger E, et al.: A randomized, doubleblind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK/ZK 222584 or placebo (CONFIRM-1) [abstract]. Proc ASCO 2005, 23:3.

    Google Scholar 

  51. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004, 351:337–345.

    Article  PubMed  CAS  Google Scholar 

  52. Fisher GA, Kuo T, Cho CD, et al.: A phase II study of gefitinib in combination with FOLFOX4 in patients with metastatic colorectal cancer [abstract]. Proc ASCO 2004. J Clin Oncol 2004, 22:3514–3520.

    Article  CAS  Google Scholar 

  53. Messersmith WA, Laheru DA, Senzer NN, et al.: Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004, 10:6522–6527.

    Article  PubMed  CAS  Google Scholar 

  54. Kooby DA, Fong Y, Suriawinata A, et al.: Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003, 7:1034–1044.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité d’Oncologie Médicale, Hôpital Huriez, CHRU, 1 rue Michel Polonovski, 59037, Lille, France

    Mohamed Hebbar MD, PhD

Authors
  1. Mohamed Hebbar MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hebbar, M. Chemotherapy in patients with resectable liver metastases from colorectal cancer. Curr colorectal cancer rep 1, 34–40 (2005). https://doi.org/10.1007/s11888-005-0014-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-005-0014-3

Keywords

Search

Navigation